Last reviewed · How we verify
Vascular Improvement With Olmesartan Medoxomil Study (VIOS)
The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.
Details
| Lead sponsor | Daiichi Sankyo |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2002-11 |
| Completion | 2005-07 |
Conditions
- Hypertension
Interventions
- olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
- atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Primary outcomes
- Subcutaneous gluteal fat arteriole measurements prior to and after 52 weeks of therapy — 52 weeks
Countries
United States